Lilly Alzheimer's drug not to be covered by U.K.'s NHS
Waldron Private Wealth LLC decreased its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 0.2% in the 3rd ...
And it looks like Johnson & Johnson (NYSE: JNJ) just hit a bump in the road that'll pave the way for Eli Lilly (NYSE: LLY) to ...
Eli Lilly has filed three new separate lawsuits accusing vendors and a medical spa of selling knock-off versions of their ...
Eastern Bank increased its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 145.8% in the 3rd quarter, according ...
As an investor in Eli Lilly stock, I'm encouraged by the company's forward thinking. Not only is management making moves to ...
Bernstein has recently initiated Eli Lilly And Co (LLY) stock to Outperform rating, as announced on October 17, 2024, according to Finviz. Earlier, on September 13, 2024, Citigroup had resumed the ...
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
MangoRx remains committed to its mission and plans to continue to enhance patient care by offering new and innovative solutions while striving to comply with federal, state and local regulatory ...
The justices are considering an effort challenging longstanding case law blocking the state’s ability to probe inflated drug ...
Eli Lilly (LLY) is suing medical spas and online vendors who claim their products contain the main ingredients of GLP-1 weight-loss drug Zepbound, according to Reuters. Lastly, Bloomberg reports ...
Eli Lilly & Co. closed $63.38 below its 52-week high ($972.53), which the company reached on August 22nd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback